Why the study?
The clinical value of clopidogrel combined with rivaroxaban in patients with lower extremity arteriosclerosis obliterans (LEASO) after endovascular intervention was unclear.
Does clopidogrel combined with rivaroxaban improve ABI and clinical parameters compared to clopidogrel plus aspirin in patients with lower extremity arteriosclerosis obliterans following endovascular intervention?
RCT (n=70)
Random number table
No
Does clopidogrel combined with rivaroxaban improve ABI and clinical parameters compared to clopidogrel plus aspirin in patients with lower extremity arteriosclerosis obliterans following endovascular intervention?
In patients with lower extremity arteriosclerosis obliterans undergoing endovascular intervention, combining clopidogrel with rivaroxaban significantly increases ABI and alters coagulation parameters without increasing adverse events compared to clopidogrel plus aspirin at 1 month.
Answers are grounded in this paper and cite their sources.
Does not support practice change post-LEASO; leaves open need for randomized trials on clinical outcomes.
摘要: 目的 探讨氯吡格雷联合利伐沙班在下肢动脉硬化闭塞症(leaso)患者中的应用价值。 方法 选取2021年1月—2024年1月烟台市莱阳中心医院收治的70例leaso患者,以随机数表法分为观察组与对照组,各35例。所有患者均接受血管腔内介入治疗,对照组采用氯吡格雷+阿司匹林治疗,观察组采用氯吡格雷+利伐沙班治疗,两组均在1个月后复查。比较两组临床疗效、红细胞、血小板、凝血酶原时间(pt)、踝肱指数(abi)、视觉模拟评分法(vas)评分、一氧化氮(no)、内皮素(et)水平及不良反应。 结果 两组总有效率比较,差异无统计学意义(p>0.05)。术前、术后1个月,两组红细胞计数比较,差异无统计学意义(p>0.05);术前,两组血小板计数、pt比较,差异无统计学意义(p>0.05);术后1个月,两组血小板计数均低于术前,且观察组低于对照组,差异有统计学意义(p<0.05)。术后,两组pt均高于术前,且观察组高于对照组,差异有统计学意义(p<0.05)。术前,两组abi、vas评分比较,差异无统计学意义(p>0.05);术后1个月,两组abi均高于术前,且观察组高于对照组,差异有统计学意义(p<0.05);术后1个月,两组vas评分均低于术前,差异有统计学意义(p<0.05),但两组vas评分比较,差异无统计学意义(p>0.05)。术前,两组血清et、no水平比较,差异无统计学意义(p>0.05);术后1个月,观察组血清et水平高于术前与对照组,观察组血清no水平低于术前与对照组,差异有统计学意义(p<0.05)。术前与术后1个月,对照组血清et、no水平比较,差异无统计学意义(p>0.05)。两组不良事件总发生率比较,差异无统计学意义(p>0.05)。 结论 氯吡格雷联合利伐沙班治疗血管腔内介入治疗后的leaso患者疗效确切,可改善患者abi、血小板与pt等指标,改善血管内皮功能,减轻患者疼痛,且安全性可靠。
No takes yet. Share an insight, caveat, or question.
黄志伟 et al. (2026) conducted an RCT in Lower extremity arteriosclerosis obliterans (LEASO) (n=70). Clopidogrel and rivaroxaban vs. Clopidogrel and aspirin was evaluated on Total effective rate (p=>0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: